

Publisher: Karger
E-ISSN: 1421-9913|52|2|87-91
ISSN: 0014-3022
Source: European Neurology, Vol.52, Iss.2, 2004-09, pp. : 87-91
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


The Treatment of Multiple Sclerosis with Beta-Interferon
Neuroepidemiology, Vol. 31, Iss. 3, 2008-08 ,pp. :








Interferon Beta-1a and Intravenous Immunoglobulin Treatment for Multiple Sclerosis in Iran
European Neurology, Vol. 52, Iss. 4, 2004-12 ,pp. :